Want to see SOLV full AI Analyst Report?
SOLV Stock Chart & Stats
$78.01
$2.46(3.15%)
At close: 4:00 PM EDT
$78.01
$2.46(3.15%)
Day’s Range― - ―
52-Week Range$62.38 - $90.00
Previous Close$80.47
Volume1.05M
Average Volume (3M)1.16M
Market Cap
$14.13B
Enterprise Value$18.25K
Total Cash (Recent Filing)$403.00M
Total Debt (Recent Filing)$5.29B
Price to Earnings (P/E)10.1
Beta0.69
Next Earnings
Nov 05, 2026EPS Estimate
1.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.22
Shares Outstanding170,223,720
10 Day Avg. Volume886,583
30 Day Avg. Volume1,155,009
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.73
Price to Sales (P/S)1.66
P/FCF Ratio-1.38K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$97.50Price Target Upside24.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)7.09
Revenue Forecast (FY)$8.22B
Bulls Say, Bears Say
Bulls Say
Profitability & MarginsSustained TTM gross and operating margin strength indicates durable pricing power and operational efficiency in core MedSurg and Dental lines. Strong accounting profitability provides capacity to invest in product development, support separation costs, and improve returns even if revenue growth moderates.
Successful M&A ExecutionThe Acera tuck‑in shows the company can integrate high-growth, high‑margin businesses, enhancing scale and margins. Repeatable M&A that delivers outsized gross margins supports long‑term revenue diversification and margin expansion versus reliance on organic mid-single digit growth alone.
Separation & ERP ProgressMaterial progress on TSA exits and system migrations reduces operational complexity and should free capital and talent post‑separation. A cleaner corporate structure and completed ERP migrations increase focus on MedTech, enabling targeted investment and a clearer path to improved free cash flow.
Bears Say
Weak Cash GenerationPersistently weak operating cash flow and negative FCF limit financial flexibility to fund separation costs, repurchases, and investment. Reliance on episodic tax/insurance timing and concentrated Q4 cash generation raises structural refinancing and execution risk absent sustained cash conversion improvement.
Elevated LeverageHigh net debt relative to cash reduces headroom for capital allocation and increases sensitivity to interest and cash‑flow variability. Leverage constrains the company’s ability to absorb separation-related outflows or fund M&A without drawing on capital markets or asset sales, raising structural financing risk.
Litigation & Timing VolatilityMaterial litigation charges directly reduce cash and reported earnings while ERP advanced‑order timing and separation activity create recurring quarter‑to‑quarter volatility. Combined legal and operational timing exposures produce sustained execution risk and unpredictable near‑term cash flows.
Solventum Corporation News
SOLV FAQ
What was Solventum Corporation’s price range in the past 12 months?
Solventum Corporation lowest stock price was $62.38 and its highest was $90.00 in the past 12 months.
What is Solventum Corporation’s market cap?
Solventum Corporation’s market cap is $14.13B.
When is Solventum Corporation’s upcoming earnings report date?
Solventum Corporation’s upcoming earnings report date is Nov 05, 2026 which is in 86 days.
How were Solventum Corporation’s earnings last quarter?
Solventum Corporation released its earnings results on Aug 05, 2026. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $1.905 by $0.645.
Is Solventum Corporation overvalued?
According to Wall Street analysts Solventum Corporation’s price is currently Undervalued.
Does Solventum Corporation pay dividends?
Solventum Corporation does not currently pay dividends.
What is Solventum Corporation’s EPS estimate?
Solventum Corporation’s EPS estimate is 1.37.
How many shares outstanding does Solventum Corporation have?
Solventum Corporation has 170,223,720 shares outstanding.
What happened to Solventum Corporation’s price movement after its last earnings report?
Solventum Corporation reported an EPS of $2.55 in its last earnings report, beating expectations of $1.905. Following the earnings report the stock price went down -5.156%.
Which hedge fund is a major shareholder of Solventum Corporation?
Currently, no hedge funds are holding shares in SOLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solventum Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$97.50 (24.98% Upside)
$97.50 (24.98% Upside)
Blogger Sentiment
Bullish
SOLV Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 301.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.96%
Trailing 12-Months
Company Description
Solventum Corporation
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
SOLV Company Deck
SOLV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive tone: the company beat expectations on top and bottom lines, raised full-year guidance (organic growth, operating margin, EPS, and free cash flow), accelerated share repurchases, showed strong segment performance (especially Dental and MedSurg) and highlighted successful M&A (Acera) and progress on separation/ERP migration and product pipeline. Notable near-term headwinds include ERP advanced-order timing that will reverse in Q3 (creating quarter-to-quarter volatility), tariff and inflation pressures (partly offset by a one-time $100M tariff refund), material litigation charges, and separation-related cash demands. Overall, management presented confidence in transformation execution and a pathway to improved cash flow and margin expansion despite measurable one-time and timing-related challenges.View all SOLV earnings summariesSOLV Stock 12 Month Forecast
Average Price Target
$97.50
▲(24.98% Upside)
Technical Analysis
DaVita
―
Fresenius Medical Care
―
Encompass Health
―
Tenet Healthcare
―
Universal Health
―
Ownership Overview
14.99% Insiders
19.91% Mutual Funds
4.83% Other Institutional Investors
39.20% Public Companies and
Individual Investors